Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis (RANGE)

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis (RANGE)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms RANGE
  • Sponsors Flexion Therapeutics; Pacira BioSciences

Most Recent Events

  • 07 May 2020 According to a Flexion Therapeutics media release, the company has decided to discontinue this study. Given the small number of patients enrolled in the trial, the uncertainty around when will the company be able to restart it, as well as the costs required to maintain the study in an inactive status, company believed in terminating the trial is the most responsible action at this time.
  • 07 May 2020 Status changed from suspended to discontinued, according to a Flexion Therapeutics media release.
  • 01 Apr 2020 According to a Flexion Therapeutics media release, the company has decided to temporarily suspend this trial due to the extraordinary impacts of the novel coronavirus global pandemic.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top